To test the antiproliferative effect of elacestrant versus fulvestrant in models of ER + BC, we used a panel of isogenic cell lines modelling sensitivity or resistance to E-deprivation (LTED) for which the PIK3CA, PTEN and ESR1 mutation status was previously established12,18 (Supplementary Table 1). The gene discussed is ESR1; the disease is breast cancer.